author-photo

Julie Dubois

University of Amsterdam

11

Papers

74

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD – Primary Analysis from the Randomized Phase II Vision HO141 Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

2020 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (15)
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)